🇺🇸 FDA

Company profile · Sponsor

Cogent

Cogent Biosciences

COGT · NYSE pharma WALTHAM, MA, USA
Pipeline
13
Drugs
0
Patents
8

Quick answer

Cogent (COGT) is a pharma company. headquartered in WALTHAM, MA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker COGT
Exchange NYSE
Company type pharma
Headquarters WALTHAM, MA, USA
SEC CIK 0001622229

Pipeline (13)

Search pipeline →

  1. CGT9486 plus sunitinib

    Cogent

    Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  2. Bezuclastinib Tablets (Formulation A)

    Cogent

    SSM

    phase 2 small molecule active

    1 trial

  3. Bezuclastinib in combination with sunitinib

    Cogent

    Gastrointestinal Stromal Tumors

    phase 2 small molecule active

    1 trial

  4. CGT4859

    Cogent

    Intrahepatic Cholangiocarcinoma (Icc)

    phase 2 small molecule active

    1 trial

  5. CGT9486

    Cogent

    Gastrointestinal Stromal Tumors

    phase 2 small molecule completed

    1 trial

  6. CGT9486, CGT9486

    Cogent

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  7. bezuclastinib

    Cogent

    Advanced Systemic Mastocytosis (AdvSM)

    phase 2 small molecule active

    1 trial

  8. ACTR T Cell Product

    Cogent

    Solid Tumor

    phase 1 mab terminated

    1 trial

  9. ACTR087

    Cogent

    Lymphoma

    phase 1 mab completed

    1 trial

  10. ACTR087

    Cogent

    Multiple Myeloma

    phase 1 mab terminated

    1 trial

  11. ACTR707

    Cogent

    Lymphoma

    phase 1 mab terminated

    1 trial

  12. CGT4255

    Cogent

    Advanced Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  13. CGT6297

    Cogent

    PIK3CA Mutations

    phase 1 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12351581

    Compounds for FGFR inhibition

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12281122

    PI3K inhibitors

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11718576

    Compositions and methods comprising resveratrol

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11339112

    Compositions and methods comprising resveratrol

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10836702

    Compositions and methods comprising resveratrol

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10449129

    Encapsulates of salicylic acid and polysalicylic acid derivatives

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10301248

    Compositions and methods comprising resveratrol

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 6610295

    Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor

    Expires Mon Aug 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is Cogent?

Cogent (COGT) is a pharma company. headquartered in WALTHAM, MA, USA. listed on NYSE. NovaPharmaNews links 13 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Cogent sponsor?

We track 13 ClinicalTrials.gov-linked programs for Cogent, including CGT9486 plus sunitinib and 12 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Cogent company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.